Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127510 · ClinicalTrials.gov registry record
Brain NAD in Alzheimer's Disease
A clinical trial of Alzheimer Disease (AD), sponsored by Florida Atlantic University.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07127510 is a study of Alzheimer Disease (AD) that is actively recruiting participants, run by Florida Atlantic University. The registered enrollment target is 20 participants, below the 261-participant average among 5 other Alzheimer Disease (AD) trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07127510, a study of Alzheimer Disease (AD), is actively recruiting participants, sponsored by Florida Atlantic University.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Conditions Studied
Study Locations (1)
Florida
- FAU Clinical Research Unit - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07127510
The ClinicalTrials.gov registry entry for NCT07127510 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 5 other Alzheimer Disease (AD) trials with a reported enrollment target (92% lower). The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease (AD) appearing as the primary indexed condition, and to 0 interventions.
NCT07127510 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07127510 about?
NCT07127510 is a clinical study titled "Brain NAD in Alzheimer's Disease". The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who d...
What is the current status of trial NCT07127510?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-12-15. Estimated completion is 2027-03.
What conditions does trial NCT07127510 study?
This clinical trial studies the following conditions: Alzheimer Disease (AD).
Who is sponsoring clinical trial NCT07127510?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127510 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
ACTIVE NOT RECRUITING
-
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
COMPLETED · Phase 2
-
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.